Active substance
Viloxazine
- SFDA 2
- US FDA 1
- US price lines 3
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VIVALAN TAB 50MG | 50 mg | Tablet · Oral use | 100 Tablet Container | SAR 17.70 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| VIVALAN TAB 50MG | 50 mg | Tablet · Oral use | 30 Blister | SAR 41.15 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| QELBREE | EQ 100MG BASE; EQ 150MG BASE; EQ 200MG BASE | capsule, extended release · oral | SUPERNUS PHARMS | Prescription | 2 Apr 2021 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | QELBREE ER 100 MG CAPSULE | $12.73257 | per EA | 23 Sep 2026 |
| US NADAC | QELBREE ER 150 MG CAPSULE | $12.731 | per EA | 23 Sep 2026 |
| US NADAC | QELBREE ER 200 MG CAPSULE | $12.73799 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 23 Jan 2025 QELBREE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.